吉利德(GILD.US)突破性长效HIV疗法在欧盟获批上市

智通财经
Aug 27
【吉利德(GILD.US)突破性长效HIV疗法在欧盟获批上市】智通财经APP获悉,吉利德科学(GILD.US)今日宣布,欧盟委员会(EC)已批准其HIV-1衣壳抑制剂Yeytuo(lenacapavir)上市,作为暴露前预防(PrEP)疗法,以降低高风险成年人和青少年(体重至少35公斤)因性传播而感染HIV-1的风险。根据新闻稿,Yeytuo为欧盟(EU)首款每年两次的HIV PrEP疗法。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10